Crinetics Pharmaceuticals, Inc. 获得分析师 50.82 美元的一致目标价。 Crinetics Pharmaceuticals, Inc. Receives $50.82 Consensus Price Target from Analysts.
覆盖 Crinetics Pharmaceuticals （纳斯达克股票代码：CRNX）的 12 家券商给予其“适度买入”一致评级，1 年平均目标价为 50.82 美元。 12 brokerages covering Crinetics Pharmaceuticals (NASDAQ:CRNX) have given it a "Moderate Buy" consensus rating, with an average 1-year price target of $50.82. JMP Securities 将目标价从 50 美元上调至 60 美元，HC Wainwright 维持“买入”评级，目标价为 42 美元，Cantor Fitzgerald 将目标价从 50 美元上调至 65 美元。 JMP Securities raised their price objective to $60 from $50, HC Wainwright maintained a "buy" rating with a $42 target price, and Cantor Fitzgerald increased its target price to $65 from $50. 摩根士丹利首次给予“增持”评级和 50 美元的目标价。 Morgan Stanley initiated coverage with an "overweight" rating and $50 target price.